Dare Bioscience, Inc.

Welcome to the conference call hosted by Dairy Bioscience to review the company's 2025 financial results and to provide a business update. This call is being recorded. My name is Desiree and I will be your operator today. With us today from Dairy are Sabrina Martucci-Johnson, President and Chief Executive Officer, and Marty Haring-Layton, Chief Accounting Officer. Ms. Haring-Layton, please proceed.

Good afternoon and welcome to the DARE Bioscience Financial Results and Business Update Call for the year-ended December 31, 2025. Today, we will review our financial results, provide updates on our clinical pipeline, and discuss the continued execution of our expanded business strategy. That strategy includes a dual-path approach, commercializing proprietary formulations through 503 compounding while pursuing FDA approval, and advancing select solutions as branded consumer health products that do not require a prescription. In all cases, our goal is to bring innovative women's health solutions to market as efficiently and quickly as possible. I would like to remind you that today's discussion will include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Any statements made during this call that are not statements of historical facts should be considered forward-looking statements. Actual results or events could differ materially from those anticipated or implied by these statements to known and unknown risks and uncertainties. You should not place undue reliance on forward-looking statements. Forward-looking statements are qualified in their entirety by the cautionary statements in the company's SEC filings, including our Form 10-K for the year ended December 31st, 2025, which was filed today. Please note that the content of this call includes time-sensitive information that is current only as of today, March 26, 2026. DARAE undertakes no obligation to update any forward-looking statements to reflect new information or developments after this call, except as required by law. I would also like to point out that when we use the term 503 compounding during this discussion, we are referring to compounding drug products by outsourcing facilities registered under Section 503 of the Federal Food, Drug, and Cosmetic Act using bulk drug substances on the FDA's Interim Category 1 list. I will now turn it over to Sabrina.

Thank you, Marty. Good afternoon, everyone, and thank you for joining us. Ten years ago, we made a decision to focus exclusively on women's health, not as a sideline, not as a franchise within a broader portfolio, as our entire reason for existing. Every dollar raised, every clinical trial run, every regulatory submission prepared, every partnership negotiated, all of it for one purpose. Building the company with the most comprehensive pipeline comprised exclusively of differentiated products for health issues and conditions that uniquely impact women. From contraception to menopause, sexual health to fertility, vaginal health to infectious disease, we're working to close critical gaps in care with science that meets her needs. What distinguishes DARE is not just the breadth of the pipeline, but the strategy behind it. A disciplined approach to capital allocation that pairs non-dilutive grant funding with focused development, moving multiple programs towards the clinic simultaneously. That's not a single product bet. That's a portfolio strategy. built from the ground up for one of the most chronically underfunded areas in all of medicine, despite affecting half the world's population. We're not a company that's just getting into women's health. We are a women's health company. And 2026 is the year investors get to see what 10 years of that commitment actually looks like. I want to take the next few minutes to share why we believe the investors who pay attention to the story right now will be glad they did. And the best place to start that story, because it's already happening in the market, is Dare to Play. Pre-sophoma prescribing for Dare to Play Sildenafil Cream went live in February 2026 across all 50 states and we're just getting started. Dare to Play is a first of its kind topical arousal cream for women. To our knowledge, there is no other silbentafil topical cream manufactured under GMP requirements with clinical data demonstrating increased general blood flow in just 10 to 15 minutes and improvements in arousal, orgasm, and desire measured by clinically validated and FDA-reviewed endpoints. Men have had Viagra in their medicine cabinet for over 25 years. Women have had nothing clinically studied and developed specifically for them until now. An estimated 20 million women in the United States alone report challenges related to genital arousal. There's not a single FDA-approved therapy that directly addresses this need, not one. And while there's not yet an FDA-approved therapy, Dare to Play was designed to fill that void, and we're making Dare to Play available as a Section 503b compounded product. In December of 2025, prescription intake commenced through the DARE Health Hub, powered by Medvantix Pharmacy, our fulfillment partner, initially in just a handful of states. That rapidly expanded. As of February 11, 2026, DARE to Play is available for pre-fulfillment prescriptions in all 50 states. Telehealth access launched at the same time, so that women in most states can now receive a Dare to Play prescription, if it's appropriate for them, without ever leaving their home. Prescribers are writing, women are engaging with telehealth, and we expect dispensing to begin in the coming months as the 503 outsourcing facility completes certain state licensing and other fulfillment preparations. Women are finding their way to the DARE Health Hub, working through the telehealth process, and providers are already submitting prescriptions. The market's getting ready before we've even opened the commercial faucet. And you may be wondering why women would want to obtain a prescription for a product that isn't even being dispensed yet when a pharmacy could compound a custom sildenafil cream for them right now. And that's the question we love because the answer is decisive. Every custom Rx pharmacy compounded prescription sildenafil cream on the market may have been formulated to fill a prescription for women. but not one of them was ever actually studied in women to evaluate whether or how it works in female physiology. They assumed it, but Dare to Play is the only formulation that's backed by published clinical studies. Dare to Play is the only product backed by clinical data in women, specifically formulated and demonstrated to increase genital blood flow within just 10 minutes of application, studied for female response, and manufactured in accordance with FDA's current good manufacturing practice regulations, or GMP, and related product quality standards. That means consistent potency and quality guidelines that custom Rx prescription pharmacy or Section 503 compounders simply cannot guarantee. Healthcare providers and women tell us the same three things about Dare to Play that uniquely resonate with them. It works fast. It was genuinely built by biotech and studied for them. And following GMP potency and quality guidelines, they like that, so they know exactly what they're getting every single time. And these are not baseless statements. They're what the clinical data show and what compliance with GMP requirements validates. Our 503B commercial model is digitally native by design. We drive consumer awareness through targeted digital marketing. Women can access DARE to Play through telehealth without an in-person office visit, a discreet and convenient option. Midvanix handles fulfillment and dispensing through the DARE Health Hub with the quality infrastructure they already have in place. The daretoplaybio.com website is the conversion engine. The conferences we attend build healthcare provider credibility and patient community simultaneously. And as we prove out what it costs us to acquire a patient digitally and how long they stay on the product, and once dispensing commences in all 50 states, we can add channels and scale spend accordingly, layering in platform distribution partnerships from a position of leverage, not dependency. And that's the playbook for a capital-efficient, strategically sequenced launch that we believe will maximize value for shareholders. As our commercial footprint grows, we expect additional strategic partnerships with telehealth platforms, platform distributors, and clinical networks. So please stay tuned. And here else is what makes our approach uniquely powerful. While Dare to Play is available for pre-fulfillment today through the 503B compounding pathway, generating real prescribing data, building clinician relationships, and creating patient demand, We continue to simultaneously work to advance our Sedentafil cream towards the 505b2 NDA pathway for FDA approval at the same time. And that's the power of building our products around well-characterized chemical entities, compounds that have established safety databases. It means we can start building a market for certain of our product candidates, and we build that market while we are simultaneously building the regulatory file. and the real-world data we generate through our 503 strategy may ultimately strengthen our NDA submission. To our knowledge, there is no company of our size in women's health that has this kind of strategic flexibility. It's a direct result of how deliberately we designed our pipeline. Dare to Play is our most immediate new revenue story, so I wanted to start there because it's happening. But now let me step back and make a broader statement about what we've built Because I believe most investors have not yet grasped the full scope of it. To our knowledge, DARE Bioscience has the most robust development stage pipeline of any company in the world, developing products exclusively for conditions that solely affect women. We have not been able to identify another company with a comparable portfolio. So let me walk you through the most advanced programs in that portfolio. In addition to 503B compounding, we're working to bring to market in the United States a line of consumer health products branded as the Dare to Restore family. Dare to Restore products are probiotics designed to support vaginal microbiome balance. Our first Dare to Restore product, FloraSync LF5, a vaginal probiotic suppository developed by Probiotical, one of the world's leading probiotic research companies, is expected to become commercially available in the United States in the second quarter of 2026 this year. The formulation is based on scientific research into the vaginal microbiome composition and health. It's been studied in a 100-person human clinical trial. Findings have been published in a peer-reviewed journal. Probiotical is the exclusive manufacturing using their proprietary LF5 strain. We believe that level of clinical evidence really distinguishes FloraSync LF5 from the majority of vaginal probiotic suppositories on the market today, and we expect it to be an important differentiator. We intend to distribute Dare to Restore products through the Dare Health Hub. These vaginal probiotic products are intended to be complementary to our 503B prescription offerings. Healthcare providers may recommend Dare to Restore products alongside Dare to Play or other DARE products. as part of a comprehensive approach to women's vaginal and sexual health. We also expect to continue exploring opportunities to expand the Dare to Restore commercial offering through additional collaborations, including with Probiotical. Dare to Reclaim is our proprietary monthly interaginal ring designed to deliver bioidentical estradiol and progesterone, targeting the estimated $2.5 to $4.5 billion compounded hormone therapy market. Women are demanding alternatives to synthetic hormones, and bioidentical hormone therapy is a category on the rise. And Dare to Reclaim is designed to be the first monthly intravaginal delivery solution in this space that includes both bioidentical estradiol and bioidentical progesterone together in one product. We're targeting to have Dare to Reclaim available for 503B prescription fulfillment in 2027. while simultaneously pursuing activities to support an IND filing for a pivotal phase three clinical study. Again, utilizing the dual path strategy of executing on both fronts at once. Imagine being the first monthly bioidentical hormone therapy intravaginal ring including both estradiol and progesterone together in that estimated 2.5 to 4.5 billion dollar market. That's what Dare to Reclaim is positioned to be. And investors can invest in that potential today. And now oviprene. Oviprene is our monthly intravaginal hormone-free contraceptive candidate. And it's among the programs that I believe carry some of the most extraordinary long-term value in our portfolio because the contraceptive market is large and it is shifting. A growing number of women, particularly younger women, are actively seeking alternatives to hormonal contraception They're demanding effective, convenient, non-implanted, non-hormonal options. That demand is real and it's growing. And the current market has nothing to offer beyond in-the-moment solutions like condoms or vaginal gels. And oviprene is in a phase three pivotal trial right now. As you may recall, the Data Safety Monitoring Board reviewed interim data in July of 2025, and they recommended that the study continue. and that we continue enrollment without modification. We are now happy to let you know that we currently anticipate enrollment to complete this year. And completing enrollment in 2026 puts a 2027 data readout in reach. And with it comes a potential PMA pathway for what could be the first non-implanted, non-hormonal monthly contraceptive option on the market. This asset alone in a world actively demanding non-hormonal contraception has partnership and licensing potential that we believe the market has dramatically undervalued. And speaking of undervalued, I want to turn to DARE HPV, which is perhaps our most underappreciated program given its potential. Roughly 6 million women in the United States alone acquire a high-risk HPV infection every year. And today, every single one of them is being managed with watchful waiting or surgery. There is no drug therapy. And that represents a completely untreated patient population with a clear clinical need and no existing direct competition in the pharmacologic space. High-risk HPV types are the underlying cause of virtually all cervical cancer cases in the United States, 99% of them. For decades, women with persistent high-risk HPV infection have been told to watch and wait, to monitor and hope that the virus clears on its own. And if it doesn't, the only recourse has been surgery once precancerous changes appear. There's not a single FDA-approved pharmacologic treatment for high-risk HPV infection, not one. And we're developing one with ARPA-H funding. With FDA clearance of our IMD application just this February of 2026, we are now preparing to advance DARE-HPV into a Phase II clinical study later this year. DARE-HPV has the potential to be the first pharmaceutical therapeutic in one of the largest unaddressed infectious disease markets affecting women globally. Significant unaddressed market, grant-funded development, Advancing into phase two, that's exactly the kind of asset that should get re-rated when investors discover it, and we believe very few have. And in addition to the portfolio programs that I just highlighted, other potential first and category contraceptive candidates currently supported entirely with grant funding, DERLARC1, CASIA-S, and activities will aid in the identification and development of a novel non-hormonal intravaginal contraceptive candidate suitable for and acceptable to women in low- and middle-income country settings who need or would prefer to use such a product to avoid an unplanned pregnancy. Those programs continue to advance with that 100% grant funding. And we also recently announced an extension of an NIH award for DARE PTB-1, which is our bioidentical progesterone intravaginal brain candidate aiming to reduce the risk of preterm birth in at-risk women. Our pipeline is deliberately built to address the most persistent gaps from preterm birth to HPV, associated disease to sexual health and beyond, and where we can use strategic non-diluted funding like the Foundation and NIH grants I mentioned and ARP-H grants to advance that work, we will. Every dollar of grant funding we secure is a dollar that moves us closer to putting better options in women's hands without diluting our shareholders. And I want to speak directly to every investor on this call, institutional, retail, and everyone who listens to the replay. We spent 10 years building this, and we did it the right way, with clinical rigor, disciplined capital management, and with an unwavering commitment to women who have been underserved by the healthcare system for far too long. And right now, in early 2026, we're at the moment where all of that investment converges into action. Products are coming live, demand is building, data is forthcoming, we're poised for partnership, and revenue is on the near-term horizon. Women represent half the global population, yet women's health receives just 6% of private health care investment. And conditions that solely affect women, the very conditions we're developing treatments for, attract less than 1%. That's not because it's a niche. That's a market failure, and it is exactly the gap that DARI was built to address. And the investors who will look back and say they saw this coming are the ones paying attention right now. Before the prescriptions become revenue, before the oviprene data reads out, before data reclaim enters the estimated $2.5 to $4.5 billion hormone therapy market, and before DARE HPV data readout. The story is being written today, and this is the catalyst stack that we're targeting to deliver this year. DARE to play dispensing, scaling nationally in the coming months, with revenue expected to begin in the second quarter of this year. Additional commercial and telehealth partnerships for Dare to Play to be announced as our channel infrastructure matures. Dare to Restore, FloraSync LF5, advancing towards commercial availability in the U.S. consumer health market in the second quarter of 2026. Dare to Reclaim, targeting 503B commercial availability in 2027 with IND preparatory activities ongoing pursuant to our dual path strategy. Ovaprene Phase 3 enrollment, expected to complete this year. And as I mentioned, completing enrollment in 2026 puts a 2027 data readout within reach. And DARE HPV, preparing to advance into Phase 2 this year with our ARPA-H funding. So this is not a single event binary bet. It's a portfolio with multiple catalysts, multiple pathways to value, and multiple ways to win. And here's what I want you to understand about our competitive position. We believe we're positioned for advantages that compound over time. With every prescription written for Dare to Play, we build the real-world data set that strengthens our NDA submission. Every overprint patient enrolled moves us closer to data that will attract partners. Every clinician who prescribes one of our products becomes an advocate for the next. We're not starting over with each product. We're building a platform. On years of clinical data, Data that is difficult to replicate. Establish relationships with telehealth providers, specialty pharmacies, and clinical KOLs in women's sexual health and vaginal health and beyond. Groundwork laid for the 505 regulatory pathway that we believe provides an opportunity to protect and expand our market positions after the 503 market matures. And brands, dare to play, dare to restore, dare to reclaim, built around clear, resonant identity with women. We're operating at a moment when the culture and commercial conversation about women's health has never been louder. The fem tech and the services sectors are attracting serious capital. Women are demanding that healthcare take their needs seriously. Payers and providers are beginning to respond and political and media attention on women's health including contraception, sexual health, and menopause, is at historic highs. And Dario Bioscience is not trying to ride that wave. We were building for it for a decade before it arrived. Our pipeline is not reactive to a trend. It foresaw the trend and exactly is what the trend is calling for. The tide's rising in women's health, and we have been building our pipeline at low tide. So investors who want in before the water rises are looking at our company right now. And with that context, I'll turn it back over to Marty for the financial review.

Thanks, Sabrina. Good afternoon, everyone. I will now walk through our financial results for the full year ended December 31st, 2025, and provide context on our balance sheet and forward financial positioning. We ended the year with approximately $24.7 million in cash and cash equivalents and working capital of approximately $3.4 million. During 2025, we received approximately $20.8 million in net proceeds from sales of common stock under our ATM facility and equity line agreement. Additionally, we received non-dilutive capital that contributed to strengthening our balance sheet in 2025, including approximately $13.6 million received from the Gates Foundation, $4.5 million received under an ARPA-H award, and $1.3 million received from NIH grant reimbursements. Together, these sources allowed us to advance multiple programs simultaneously while managing shareholder dilution responsibly. Selling general and administrative, or SG&A, expenses for the full year were $8.8 million compared to $9.2 million in 2024. The year-over-year change was primarily driven by decreases in stock-based compensation expense, personnel costs, and general corporate overhead expenses. Such decreases were partially offset by increased commercial readiness expenses primarily for Dare to Play and increased professional services expenses. Research and development or R&D expenses were $5.5 million for the full year compared to $14.3 million in 2024. I want to highlight an important feature of our R&D expense reporting. We recognize non-dilutive funding awards as contra R&D expense, meaning grant funding directly offsets our reported R&D costs on our income statement. In practical terms, this means we are investing more in R&D than our reported R&D expense line suggests. Contra R&D expense, reflecting grant dollars received, was $13.9 million in 2025 compared to $7.7 million in 2024. In other words, while reported R&D expenses declined year over year, our actual total R&D investment, when you add back contra R&D amounts, was much closer between 2025 and 2024 than the R&D expense line alone reflects. We believe this is an important dynamic for investors to understand when evaluating our capital efficiency with the use of grant funding and the true scale of our R&D investments. We expect to begin recording product revenue from Dare to Play in Q2 2026 as dispensing commences nationally. FloraSync LS5 consumer health revenue is also expected to begin in Q2 2026. We are targeting to begin recording revenue from Dare to Reclaim in 2027. We are building toward a multi-product revenue profile that diversifies and grows across 2026 and 2027. We encourage investors to review the more detailed discussion of our financial statements, financial condition, liquidity, capital resources, and risk factors in our Form 10-K for the year ended December 31, 2025, filed today. Operator, please open the line for questions.

Thank you, Marty. We will now begin the question and answer session. If you have dialed in and would like to ask a question, please press star 1 on your telephone keypad to raise your hand and join the queue. If you would like to withdraw your question, simply press star 1 again. If you are called upon to ask your question and are listening via speakerphone in your device, please pick up your handset to ensure that your phone is not on mute when asking your question.

Again, press star 1 to join the queue.

Our first question comes from the line of Catherine Novak with Jones Trading. Your line is open.

Hi, this is Leona on for Catherine. Thank you for taking our questions. When was your last interaction with FDA on sildenafil cream? And what are the next steps for clinical development and the 505 regulatory path? And I'll ask a follow up after.

Thanks. Thanks for the question. So this is a reminder of everyone. So we did have interactions with the FDA last year and really at this point, What we are looking at with that program is making sure that we're 100% aligned on the endpoints, the primary endpoint for the trial, and not so much the arousal part. Our arousal questions are really clear and straightforward, but what else in terms of any kind of interpersonal challenges should constitute part of that co-primary assessment, and how specifically that's going to be analyzed for part of the statistical, like as it pertains to the statistical analysis plan and success. So, you know, we want to make sure that we're very clearly aligned on that. And our interactions with the FDA, particularly the last set of interactions in 2025, were really to make sure that we were sharing and providing and discussing together the various assessments that were included, not only in the Phase 2B study, but also the work we had done prior to that in the content validity study, which really is a study that helps you ascertain what questions are content valid and fit as patient-reported outcomes to make sure that we're all thinking together about a full picture of what makes sense for this particular indication, which is really focused on improvement of genital sensations of arousal. very analogous, couldn't be more analogous to erectile dysfunction because the clinical definitions are the same. And so we're working closely with the FDA to make sure that there are endpoint frameworks that are reflective of the similarity between the conditions and the unmet needs.

Okay, got it.

So that dialogue is ongoing. Yeah, thank you.

Okay. And then do you need to conduct any additional safety studies, or will the submission rely on existing data for systemic sildenafil in women?

Yeah, the data we've collected from a safety perspective and what would be planned in the Phase 3 would certainly be sufficient. I mean, one of the things that has been, I would say, fantastic about being able to formulate a product like this into a topical formulation that achieves the blood flow objectives that we want is that it's really been designed to target those tissue and get that very rapid increase in temperature that we've seen quantitatively in the published study, you know, within that first 10 to 15 minutes of application without really significant systemic uptake. In effect, we're, you know, two orders of magnitude lower than what you would see with a comparable sort of oral dose as seen in the male studies. And that's really been the objective is to make sure that we keep that systemic exposure very low so we don't get those off-target effects of headache and flushing that would, you know, not be supportive of the objective of the product in terms of enhancing arousal, but we just get that localized effect. And so we really did not see any difference in the Phase 2b study and the safety data are all published between the placebo group and the active group. in terms of adverse event profile.

Okay, thank you so much. Yeah, thank you.

Our next question comes from the line of Camp Deliver with Brookline Capital Markets. Your line is open.

Thank you. What are you seeing with the order patterns so far for Dare to Play?

Yeah, great question, and one we anticipated, and they're excited to get to talk about. And what's been exciting about it, I would say, is that we're in this pre-fulfillment phase for the product while our 503B collaborator continues certain activities. So prescriptions are coming in, but they're not being dispensed yet. And what has been exciting about it is that we're seeing a mix of Prescriptions coming in from brick-and-mortar providers, people that we have been engaging with at conferences who have gotten to know the product and are excited to write it for their patients when they see their patients, even though it's not dispensing yet, but they want to make sure they get that prescription in for their patient, and they want to make sure that they are letting their patient know that there's a solution like this that is going to be available for them that actually has clinical data, has published peer-reviewed findings, as well as women engaging with telehealth. So we're really seeing that both of those channels are active and relevant. And so that's been really helpful for us to understand and particularly early in this awareness and education It's been very nice to be able to have these kind of data to help us see that both channels are important because this is a product that resonates with a healthcare provider. It has the data. It has the peer-reviewed publications that they look to, and we don't have to solely rely on a consumer channel and to see the breadth of both. So more to follow on that as these convert to orders, as they start dispensing. And we will, in the coming months, be able to and start to provide more clarity, as I alluded to, in terms of that channel strategy, that approach, acquisition costs. But right now, the focus has been on that very digital-focused campaign to make sure that consumers are aware of what's available, but also we've really been attending the conferences and doing the provider-to-provider education that is very relevant for a product like this that has published clinical data in their most trusted journals for products like this.

And how are you thinking about promoting Dare to Restore? which really looks, as you say in the press release, it's a consumer slash OTC product.

Great. Another great question. And you've really hit something important, which is it does not require a prescription, right? These are products that consumers, these types of products are something that a consumer is a little more familiar with. I will say it's also in a category of products that a number of consumers are do also engage with their healthcare provider to understand what their healthcare provider recommends. And so we're going to be able to leverage here some of the same channels that we're leveraging for Dare to Play. It'll certainly appear on the DARE Health Hub, which is where someone who's getting a Dare to Play prescription will be going. So it'll appear right there as something that can also be purchased at the same time. We will also be similarly engaging in a very digital native sort of strategy in terms of creating very focused and targeted strategy in the digital channels to create awareness and drive conversion through the DARE Health Hub and through the website. But also we will be participating in medical conferences and showcasing this product at those conferences because it is very distinct In in the fact that there are peer-reviewed published data on both the strain itself and on the final finished formulation and we think that's something that healthcare providers will be very interested in and there is a whole category of healthcare providers that are Starting to recognize that for some women, you know, they may be interested in obtaining products while they're in that office visit right with that healthcare provider and And so those are other channels that we're also looking at, very analogous to, you know, the derm space is very mature, right, in that regard in terms of the kind of products that are sometimes also available in your clinician's office. And so for those clinicians where this becomes, you know, a very trusted solution for them, we see those channel opportunities as well.

Our next question comes from the line of Douglas Chow with HC Wainwright. Your line is open.

Hi, good afternoon. Thanks for taking the questions. Sabrina, I guess I dare to play, you know, it sounds like you're doing a lot of work in terms of physician education. I know you've also done some work with different online sort of platforms as well. I guess, how do you envision or what do you see as the bigger driver of volume ultimately? Will it be some of the different sort of telehealth and sort of subscription model platforms, or do you see it being more driven by, you know, prescribers?

Yeah, it's a fantastic question, and it's something that we have been looking at very closely and monitoring very closely. And as I noted in the comments, one of the things that we want to make sure that we understand very clearly as we look at these various platforms is making sure that we understand in the channels that we have available to us today, as well as what those conversations look like, right, with those other telehealth providers and platforms, what the patient acquisition cost, customer acquisition cost is in those various platforms. scenarios paired with their reach, right, kind of their reach and the number of touch points that they have. And what we want to make sure that, you know, once dispensing commences in all 50 states, right, that we have all of those, you know, it's available in all of the states and we've been collecting all of these data, that we're making sure that we're layering in these partnerships with a financial structure that makes sense to extend the reach and the touch points for the product, but in a smart structure that takes into consideration the various acquisition costs in the channels that we have been in already, as well as the reach in those channels. And so it's really coupling all those factors together, right? How many patients, right? How many touch points, how many users do they already have on a particular platform, right? What is that relationship going to look like with them to access those people? Where do the cultures align and this product fit nicely? I feel like there's a new telehealth platform stance stood up every day practically for women's health right now because it's become a very hot area. And we want to make sure that there's financial stability, there's solid alignment culturally and with the product fit, and that, again, there's a financial structured model that makes a lot of sense from a cost of acquisition perspective and reach for this product. And so those are the things that we've been evaluating. And we do, you know, we want to make sure that the product is available in all of the channels that make a lot of sense, both in terms of reach and demand, and to make sure, you know, it's available where women are going for their care. So those are the factors that we're looking at.

And I guess as a follow-up question, and I hear your point earlier in terms of you're the only product that's actually been tested. I mean, I guess it's hard and, you know, it's like thinking about like, you know, so the GLP-1 class, right, where there's a lot of compounded products out there as well. You know, how do you necessarily, but I think, you know, with your product, there are arguably more formulation differences that are, arguably more important, right, to distinguish, you know, your product from other products that are out there. You know, how are you able to or how are you thinking about being able to convey that message very broadly to sort of make sure that, you know, patients don't try some of the alternative formulations and sort of give up on, you know, sort of the topical sildenafil and ultimately sort of, you know, market share coalesces around your product? Thank you.

Yeah, absolutely. Fantastic question. So, and you kind of hit the nail on the head in two ways. So one, you know, on the one hand, the GLP-1 experience that people have had have given people perhaps an impression that, you know, you can go anywhere, right, and get the same product. But of course, there are already initiatives underway in that category to educate around that and make sure it's aware. But you also touched on something super important with regard to This formulation, which has been very compelling to people, and it's very easy, both for healthcare providers, and we've found it's very easy messaging with the consumer to explain that when you're putting something on your skin, the formulation matters. Women have used a lot of different topical products. We use face creams every day. We use whatever. Right? And being able to explain that what is key here is that this is a very important medicine that needs to get into the skin and that you can't just mix something together and do that. And what really resonates more than that statement is the fact that we have clinical data demonstrating increase in blood flow, which is basically a surrogate for, right, the arousal sensations that the blood flow is going to cause within 10 minutes. And when a clinician or a consumer looks at any compounded sildenafil cream product that is not Dare to Play with our Dermaflux technology inside of it to drive that sildenafil into the tissue, they all talk about put it on at least 30 minutes before or longer because they don't have the data. That time factor resonates more than anything. And so with a healthcare provider, we're able to get into that more precisely complex conversation with them around the clinical work that's been done and the formulation technology and why that matters, that resonates very clearly with them and they understand it. And with the consumer, it's really about time to effect and that there are, this has been engineered by biotech specifically for them.

So I guess as a follow-up though, so in terms of you know, clinicians, I guess that sort of requires sort of traditional sort of, you know, sales promotion slash detailing. And with consumers, I guess it is some generally kind of mixed through DTC advertising. And are you able to sort of defray some of that cost? Because DTC can be expensive with some of the different sort of e-health or partner, you know, sort of partnerships that you have in place to help with those costs.

Yeah, absolutely. And the other way to think about this, again, the world has really changed significantly in terms of, and I'm going to refer to the influencer space, and I don't mean influencers who have, I don't know, no knowledge of clinical science or medical science, but I'm talking about healthcare providers who have very significant followings because they have been Educators and are sharing knowledge in an area that women are very desperate and hungry to get information around so These are the kind of channel like when we're talking about Enhancing our digital, you know our focus around education These are a lot of the channels that that we that you'll be seeing more and more right as this product starts dispensing better getting utilized because these are trusted clinicians, trusted voices that are looking for brands, products, solutions that they can get behind. And I think the other thing to really highlight, and we have seen this at every conference that we've been to, Dare to Play is one product, but Dari Bioscience is a brand in and of itself, right? We've run so many clinical trials. So many healthcare providers have worked with us on one of our studies, right? They are proudly telling their friends, their peers about the product. So we're also very much leveraging, I would call it provider-to-provider education and provider-to-provider promotion, marketing, for lack of a better word, because we have credibility as a builder of solutions for the women that they serve. And many of them have worked with us And that's not, you know, that's not something that, you know, a compounder, for instance, is going to be able to do.

And it really resonates.

Okay, great. Thank you very much. Yeah, absolutely.

That concludes the question and answer session. I would like to turn the call back over to Sabrina Martucci-Johnson for closing remarks.

Well, thank you. And I definitely want to close with something that I feel deeply. And it ties into some of the questions that we just went through, right? So women's health has been dismissed. It's been deprioritized. It's been underfunded for generations. And the conditions that we address at DARI Bioscience, arousal, vaginal health, menopause, contraception, HPV, these are conditions that affect millions of women worldwide. They're not rare. They're common experiences that have been met far too often with inadequate options, clinical dismissal, lack of data, or simply nothing at all. And DARI Bioscience was founded on the belief that women deserve better, and that belief has guided every decision we have made. I started DARI because I believe women's health was both a moral imperative but also a compelling strategic opportunity. And 10 years in, I believe that more than ever, Dare to Play is entering the market. And as we just discussed, women are getting prescriptions and clinicians are engaging. And telehealth is live and is a great access path. And the pipeline behind Dare to Play, it's deep, it's differentiated, and we're finding ways to advance it. So we built this company to really change how women experience health care. And that change is beginning in earnest now. And so to our investors, thank you for your confidence and for being owners. We believe the assets we hold, the catalysts that I outlined that are coming up, and this window of time that we are in represent a compelling opportunity. And we intend to execute on it. So it's 10 years of building, but the commercial inflection is here, and the pipeline is deep, and the market is ready. And DARI Bioscience in 2026 is a story that is just beginning to be told. And I think the investors who had conviction in the first chapter will be the ones who remember this call. So I thank you all for participating today and look forward to more updates in 2026.

Ladies and gentlemen, that concludes today's call. Thank you all for joining and you may now disconnect.